Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 0.66 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.66 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.48 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.48 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190163 | 0.80 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL189814 | 0.77 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL190093 | 0.77 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1MAPT | |
| SCHEMBL2529997 | 0.76 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL1221106 | 0.75 | NOTUM (0.49) | CYP11B1CYP11B2CYP2A6CYP2B6CYP1A2 | |
| SCHEMBL1024261 | 0.74 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL190075 | 0.74 | CYP11B1 (0.72) | CYP11B1CYP11B2CYP17A1CYP19A1TBXAS1 | |
| SCHEMBL1221380 | 0.74 | NOTUM (0.49) | CYP11B1CYP11B2POLBMAPT | |
| SCHEMBL1221465 | 0.74 | DRD2 (0.52) | POLBCYP2D6 | |
| SCHEMBL1221304 | 0.73 | HRH3 (0.54) | POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178877-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GlaxoSmithKline LLC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | LEIVERS MARTIN ROBERT | 2010-02-04 | — | — | US | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2009011787-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | HAVCR2, SARS1, RPL35 | CYP11B1 617/4885CYP11B2 587/4885CYP17A1 1884/4885 |
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, RPL35 | CYP11B1 617/4885CYP11B2 587/4885CYP17A1 1884/4885 |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | CYP11B1 617/4885CYP11B2 587/4885CYP17A1 1884/4885 |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | RPL35, HAVCR2, RPL5 | CYP11B1 1073/4885CYP11B2 1237/4885CYP17A1 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.